The lung disease therapeutics market size was estimated at US$ 81.24 billion in 2022 it is predicted to grow at a CAGR of 6.06% from 2023 to 2032 to reach around US$ 146.31 billion by the end of 2032.
The lung disease therapeutics market report offers an exclusive study of the present state expected at the market dynamics, opportunities, market scheme, growth analysis and regional outlook. The report presents energetic visions to conclude and study the market size, market aspiration, and competitive environment. The research also focuses on the important achievements of the market, research & development, and regional (country by country) growth of the leading vendors operating in the market
The study offers intricate dynamics about different aspects of the global lung disease therapeutics market, which aids companies operating in the market in making strategies development decisions. The study also elaborates on remarkable changes that are highly anticipated to configure growth of the global lung disease therapeutics market during the forecast period. It also includes a key indicator analysis that highlights growth prospects of this market and approximate statistics related to growth of the market in terms of value (US$ Bn) and volume (tons).
Sample Link @ https://www.visionresearchreports.com/report/sample/40337
Report Scope of the Lung Disease Therapeutics Market
| Report Coverage | Details |
| Market Size in 2022 | USD 81.24 billion |
| Revenue Forecast by 2032 | USD 146.31 billion |
| Growth rate from 2023 to 2032 | CAGR of 6.06% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Companies Covered | Johnson & Johnson, Amgen Inc., AstraZeneca, Boehringer Ingelheim, Pfizer Inc., Allergan Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Hoffmann-La Roche, Merck & Co, Teva Pharmaceutical Industries Ltd., AbbVie, Inc., Novartis AG |
This study covers an elaborate segmentation of the global lung disease therapeutics market, along with important information and a competition outlook. The report mentions company profiles of players that are currently influence the global lung disease therapeutics market, wherein various developments, expansions, and winning strategies practiced and execute by leading players have been presented in detail.
Market Segmentation
By Disease Type
- Asthma
- Lung Cancer
- Chronic Obstructive Pulmonary Disease (COPD)
By Drug Class
- Corticosteroids
- Bronchodilator
- Antimicrobial
- Alkylating Agents
- Mucolytics
By Molecule Type
- Small molecules
- Biologics
By Treatment Type
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Radiation Therapy
By Distribution Channel
- Online
- Hospital
- Retail
By Regional
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Research Methodology
The research methodology acquire by analysts for assemble the global lung disease therapeutics market report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts study numerous annual report declaration, white papers, market association declaration, and company websites to obtain the necessary understanding of the global lung disease therapeutics market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Lung Disease Therapeutics Market
5.1. COVID-19 Landscape: Lung Disease Therapeutics Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Lung Disease Therapeutics Market, By Disease Type
8.1. Lung Disease Therapeutics Market, by Disease Type, 2023-2032
8.1.1. Asthma
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Lung Cancer
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Chronic Obstructive Pulmonary Disease (COPD)
8.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Lung Disease Therapeutics Market, By Drug Class
9.1. Lung Disease Therapeutics Market, by Drug Class, 2023-2032
9.1.1. Corticosteroids
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Bronchodilator
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Antimicrobial
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Alkylating Agents
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Mucolytics
9.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Lung Disease Therapeutics Market, By Molecule Type
10.1. Lung Disease Therapeutics Market, by Molecule Type, 2023-2032
10.1.1. Small molecules
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Biologics
10.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Lung Disease Therapeutics Market, By Treatment Type
11.1. Lung Disease Therapeutics Market, by Treatment Type, 2023-2032
11.1.1. Chemotherapy
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Immunotherapy
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Targeted Therapy
11.1.3.1. Market Revenue and Forecast (2020-2032)
11.1.4. Radiation Therapy
11.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Lung Disease Therapeutics Market, By Distribution Channel
12.1. Lung Disease Therapeutics Market, by Distribution Channel, 2023-2032
12.1.1. Online
12.1.1.1. Market Revenue and Forecast (2020-2032)
12.1.2. Hospital
12.1.2.1. Market Revenue and Forecast (2020-2032)
12.1.3. Retail
12.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 13. Global Lung Disease Therapeutics Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.1.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.1.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.1.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.1.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.1.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.1.6.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.1.6.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.1.7. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.1.8. Rest of North America
13.1.8.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.1.8.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.1.8.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.1.8.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.1.8.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.2.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.2.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.2.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.2.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.6.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.2.7. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.2.8. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.2.9.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.9.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.2.10. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.2.11. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.2.12.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.12.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.2.12.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.2.13. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.2.14.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.14.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.2.14.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.2.15. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.3.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.3.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.3.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.3.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.6.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.3.6.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.3.7. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.3.8.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.8.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.3.8.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.3.9. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.3.10.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.10.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.3.10.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.3.10.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.3.11.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.11.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.3.11.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.3.11.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.4.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.4.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.4.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.4.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.6.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.4.6.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.4.7. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.4.8.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.8.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.4.8.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.4.9. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.4.10.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.10.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.4.10.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.4.10.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.4.11.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.11.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.4.11.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.4.11.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.5.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.5.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.5.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.5.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.5.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.5.6.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.5.6.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.5.7. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.5.8.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.5.8.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.5.8.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.5.8.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
Chapter 14. Company Profiles
14.1. Johnson & Johnson
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Amgen Inc.
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. AstraZeneca
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Boehringer Ingelheim
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Pfizer Inc.
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Allergan Inc.
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Bristol-Myers Squibb Company
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Eli Lilly and Company
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Hoffmann-La Roche
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Merck & Co
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Contact Us:
Vision Research Reports
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168